Ciliary neurotrophic factor (CNTF)-based curative therapy for autoimmune diabetes (TIDM):  Ciliary neurotrophic factor (CNTF)  increases the expression of PD-L1, decreases the expression of TXNIP, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 18/June/2019, 10.56 pm

Solving a century-old puzzle as to how Sesame oil functions as a pain reliever: Mechanistic insights into how Sesame oil-derived compounds function as pain medications: A pharmaceutical mixture encompassing Sesamin and Sesamol (SAS), derived from Sesame seed or oil,  increases the expression of PD-L1, decreases the expression of Cox-2, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 17/June/2019, 12.58 pm
June 17, 2019
Mechanistic insights into how Liraglutide aids in remission of Diabetes: Liraglutide (brand name: Victoza, Saxenda and others), a  drug used in the treatment of type II diabetes, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia, via downregulation of  Sox4 and its target gene Amysin,  20/June/2019, 7.13 am
June 20, 2019
Show all

Introduction: What they say

A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan 20157, Italy; and Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA shows that “PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.” This research paper was published, in the 15 November 2017 issue of the journal “Science Translational Medicine” [One of the best research journals in Science with an I.F of 15 plus], by Prof. Fiorina P and Nasr MB and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Ciliary neurotrophic factor (CNTF)-based curative therapy for autoimmune diabetes (TIDM):  Ciliary neurotrophic factor (CNTF)  increases the expression of PD-L1, decreases the expression of TXNIP, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene

[easy_payment currency=”USD”]


From significance of the study to public health relevance:

Given that: (1) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (2) Type 1 Diabetes (T1DM) constitutes about 5-10% (11 to 12 million) of all diabetic cases; (3) the incidence of T1DM is exponentially increasing year after year by 3%; (4) Diabetes is going to be one of the top 10 causes of death by 2030; (5) the life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, while treatment for T1DM costs about $15 billion dollars per annum, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM;(ii) a side-effect-free natural product-based drug that does not harm or deplete adult stem cells; and (iii) a way to cure, not just treat, diabetes.


What is known?

Prof. Fiorina’s research team has recently shown that:(1) programmed death ligand 1 (PD-L1), the immune checkpoint regulator, is expressed poorly in hematopoietic stem and progenitor cells (HSPCs) of Type-1 diabetic (T1D) patients; (2) PD-L1 inhibits activated T-cells and thereby promotes immune tolerance; (3) the expression of PD-L1 is controlled by a network of miRNAs; (4) attenuating the expression of one of the miRNAs that target PD-L1 restores the expression of PD-L1 in HSPCs; (5) increasing the expression of PD-L1 in HSPCs, either genetically or pharmacologically, inhibits autoimmune response and reverses autoimmune diabetes; and (6) PD-L1 is expressed poorly in human HSPCs of T1D patients, suggesting that increasing the expression of PD-L1 in T1D patients may reverse and cure T1D.


From research findings to Therapeutic opportunity:

Ciliary neurotrophic factor (CNTF) has  not only been shown to function as a strong survival factor for neurons and oligodendrocytes, but also been shown to  promote substantial weight loss and reduce food intake. However, the mechanistic basis of this remains largely obscure. 

This study suggests, for the first time, that  CNTF, by increasing the expression of its target gene, it may increase the expression of PD-L1 and decrease the expression of TXNIP. Thereby, it may: (1) increase Regulatory T-cells(Tregs) function; (2) decrease immune activation; (3) increase pancreatic-β-cell proliferation and regeneration; (4) increase expression of genes that promote insulin sensitivity and insulin secretion;(4) decrease metabolic stress; and (5) promote glucose homeostasis (Fig.1).Thus, CNTF inducers or its recombinant version rhCNTF (trade name: Axokine), either alone or in combination with other drugs, can be used to treat TIDM (Fig.2.), and it may function as a curative therapy for TIDM.

Figure 1. Mechanistic insights into how Ciliary neurotrophic factor (CNTF)  inhibits  the development of autoimmune diabetes. CNTF, by increasing the expression of its target genes, it may increase the expression of PD-L1 and other anti-diabetic genes and decrease the expression of TXNIP. Thereby, it may prevent immune activation and attenuate the development of T1DM

Figure 2. CNTF functions as an anti-diabetic agent by up regulating the expression of PD-L1 and other anti-diabetic genes, while down regulating the expression of TXNIP.

Figure 3.  While pharmacological intervention induces PD-L1 and ameliorates autoimmune diabetes, CNTF functions as an anti-diabetic agent by up regulating the expression of PD-L1 and other anti-diabetic genes, and by down regulating the expression of TXNIP.

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Undisclosed information: How does  CNTF increase the expression of PD-L1?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,  Ciliary neurotrophic factor (CNTF)-based curative therapy for autoimmune diabetes (TIDM):  Ciliary neurotrophic factor (CNTF)  increases the expression of PD-L1, decreases the expression of TXNIP, augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 18/June/2019, 10.56 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.